As SpaceX impacts Ukraine and AI-generated music divides artists and fans, critics are asking what happens when technology has too much control over our lives

• This was originally published in TechScape, a newsletter about how technology shapes our lives. Sign up to receive it here

Hello, and welcome to TechScape. I’m Blake Montgomery, US tech editor at the Guardian, writing to you while sitting in front of Roy Lichtenstein’s monumental Drowning Girl, on view in New York City. Today in tech, we’re discussing the perils of Elon Musk’s one-man global infrastructure, AI-generated music and a Guardian AI conference in Paris.

Use of tools ‘may result in the transfer of sensitive data’ to China, defense department says

The US government on Monday ordered its agencies to stop using artificial intelligence (AI) tools from the Chinese startup DeepSeek, as the countries race for dominance in the fast-moving sector.

A notice from the Department of Homeland Security (DHS) announced the ban on products developed by DeepSeek – and tools created using DeepSeek by third parties – saying they must be removed from IT devices.

In his annual speech on threats to the nation, Sir Ken McCallum, the head of the UK’s intelligence service, MI5, warned that AI had the potential to ‘change the stakes’ on existing and even new bioweapons. To find out why, and how, Ian Sample speaks to Dr Tom Inglesby, director of the Johns Hopkins Center for Health Security and the Bloomberg School of Public Health. He explains what has governments so worried and what measures could be put in place to reduce the risks

Could AI ‘change the stakes’ in the development of bioweapons?

Support the Guardian: theguardian.com/sciencepod

System can estimate a person’s biological age and predict chances of cancer survival from a single photograph

Doctors have developed an artificial intelligence tool that can predict a cancer patient’s chances of survival from a single photograph of their face.

The AI system was custom-built by experts at Mass General Brigham, a nonprofit, integrated academic healthcare system in Massachusetts, to estimate biological age and directly predict survival outcomes in patients diagnosed with cancer.